Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 3/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28877728 | 0.91 | SLC1A1 (0.49) | TSHRSLC1A1LMNAKDM4EKMT2A | |
| SCHEMBL2948709 | 0.89 | TSHR (0.50) | TSHRSLC1A1LMNAKDM4EKMT2A | |
| SCHEMBL12534353 | 0.89 | TSHR (0.50) | TSHRSLC1A1LMNAKDM4EKMT2A | |
| SCHEMBL12534390 | 0.88 | SLC1A1 (0.46) | TSHRSLC1A1LMNAKDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL4740477 | 0.87 | SLC1A1 (0.49) | TSHRSLC1A1LMNAKDM4EKMT2A | |
| SCHEMBL10941376 | 0.87 | SLC1A1 (0.49) | TSHRSLC1A1LMNAKDM4EKMT2A | |
| SCHEMBL10941385 | 0.87 | SLC1A1 (0.49) | TSHRSLC1A1LMNAKDM4EKMT2A | |
| SCHEMBL21015017 | 0.86 | ALDH1A1 (0.49) | TSHRSLC1A1KMT2AMEN1CA12 | |
| SCHEMBL4957134 | 0.85 | — | — | |
| SCHEMBL12636356 | 0.85 | SLC1A1 (0.51) | TSHRSLC1A1LMNAKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150112051-A1 | CONSTRUCTION OF CELL PENETRATING NUCLEIC ACIDS | Panzner, Steffen | 2015-04-23 | — | — | US | disclosed |
| US-20150112051-A1 | CONSTRUCTION OF CELL PENETRATING NUCLEIC ACIDS | Panzner, Steffen | 2015-04-23 | — | — | US | disclosed |
| EP-2526096-B1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2015-04-22 | — | — | EP | disclosed |
| US-8957191-B2 | Nucleic acid comprising zwitterionic nucleotides | STEFFEN PANZNER (DE) | 2015-02-17 | — | — | US | disclosed |
| US-8957191-B2 | Nucleic acid comprising zwitterionic nucleotides | STEFFEN PANZNER (DE) | 2015-02-17 | — | — | US | disclosed |
| US-8729091-B2 | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130150372-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8420647-B2 | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| WO-2011089099-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-28 | — | — | WO | disclosed |
| US-20110178089-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110137019-A1 | NUCLEIC ACID COMPRISING ZWITTERIONIC NUCLEOTIDES | BIONTECH PROTEIN THERAPEUTICS GMBH (DE) | 2011-06-09 | — | — | US | disclosed |
| US-20110137019-A1 | NUCLEIC ACID COMPRISING ZWITTERIONIC NUCLEOTIDES | BIONTECH PROTEIN THERAPEUTICS GMBH (DE) | 2011-06-09 | — | — | US | disclosed |
| EP-2143726-A1 | Nucleic acid comprising zwitterionic nucleotides | Novosom AG (DE) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150372-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | P2RY1, GPBAR1, ADORA1 | TSHR 1538/4885SLC1A1 607/4885LMNA 2130/4885 |
| US-20110137019-A1 | NUCLEIC ACID COMPRISING ZWITTERIONIC NUCLEOTIDES | NSUN3, NCL, NUDT1 | TSHR 1458/4885SLC1A1 169/4885LMNA 271/4885 |
| US-20110178089-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | P2RY1, GPBAR1, ADORA1 | TSHR 1538/4885SLC1A1 607/4885LMNA 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.